The 2020 Basic Science Year in Review covered autoantibody origin and persistence, insights into the major histocompatibility complex and factors in rheumatoid arthritis progression and relapse.
Coronary Microvascular Dysfunction May Predict Heart Disease in Rheumatoid Arthritis
Cardiovascular disease (CVD) is a leading cause of death in patients with rheumatoid arthritis (RA). Patients with RA have a 1.5 times increased risk for heart attack compared with the general population. Although the treatment of RA has advanced significantly, the ability to prevent cardiovascular events hasn’t followed. A study in Arthritis Care & Research…
Study Probes Utility of Neutrophil Biomarkers in Rheumatoid Arthritis
Neutrophils, often hailed as guardians against infections, are maligned when it comes to rheumatoid arthritis (RA) due to their role in both the initial stage and disease progression. A new multicenter work, “A Neutrophil Activation Biomarker Panel in Prognosis and Monitoring of Patients with Rheumatoid Arthritis,” seeks to expand the literature on this topic.1 The…
Mitigating Preeclampsia Risk May Reduce Preterm Birth, Cesarean Delivery
Interventions targeted at mitigating the risk of preeclampsia may reduce preterm birth and cesarean delivery in women with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and psoriasis. That’s one key finding of a retrospective study published in Arthritis Care & Research.1 The study set out to quantify the mediated effects of autoimmune conditions on adverse…
Study Elucidates Potential Flare Pathways in Rheumatoid Arthritis
Research in The New England Journal of Medicine has opened new avenues for exploring the pathophysiology of disease flares in rheumatoid arthritis.1 Through longitudinal genomic analysis, researchers have identified a naive B cell signature prior to rheumatoid arthritis flares, as well as a type of mesenchymal cell, that may play an important role in flare…
The Leading Boldly Fundraising Campaign Makes Tremendous Progress
In 2018, the Rheumatology Research Foundation embarked on its third and most ambitious fundraising campaign, the Leading Boldly: Transforming Rheumatology campaign, with a goal of raising $75 million over five years. The campaign supports Foundation programs to recruit the best and brightest into the field, train rheumatology health professionals at all career stages and support…
VEXAS: A Newly Identified & Vexing Myeloid-Driven Inflammation
A large, international team of rheumatologists, geneticists, hematologists and other researchers has discovered a severe inflammatory syndrome linked to an acquired genetic mutation in the bone marrow of older men. The X-linked syndrome, they found, is caused by a somatic mutation in myeloid stem cells that hobbles the master regulator of a pathway tasked with…
The Glass Ceiling in Academic Rheumatology
Gender plays a role in career advancement among academic rheumatologists in the U.S., according to a new study by Jorge et al.
A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review
During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.
Pulmonary Adverse Events with Low-Dose Methotrexate
In this large placebo-controlled trial, Sparks et al. examined the predictors and severity of pulmonary adverse events (AEs) in patients taking low-dose MTX. The researchers found that low-dose MTX increased the risk of pulmonary AEs, including possible pneumonitis.
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 123
- Next Page »